Takeda Canada Inc. announced positive topline results from the Phase 3 LATITUDE Atlas study, demonstrating that its investigational oral TYK2 inhibitor zasocitinib (TAK-279) achieved statistical superiority over deucravacitinib for all primary and key secondary endpoints in adults with moderate-to-severe plaque psoriasis.
Key Efficacy Results
At week 16, more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), a rate more than 2.5 times higher than that of deucravacitinib. The study also showed statistical superiority for the primary endpoint of PASI 100 response, as well as for key secondary endpoints including PASI 90 and sPGA 0.
The randomized, multicenter, double-blind trial enrolled 606 participants across eight countries, including 73 patients at 18 sites in Canada.
Safety Profile
Zasocitinib was generally well tolerated, with a safety and tolerability profile consistent with previous studies. No new safety signals were identified.
Expert Commentary
“For patients living with moderate-to-severe plaque psoriasis, achieving complete skin clearance remains an important treatment goal,” said Dr. Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health and principal investigator for the study. “These head-to-head Phase 3 results are encouraging because they show the potential for an oral therapy to deliver high levels of skin clearance.”
Thiago Magalhães, Head of Specialty BU at Takeda Canada, added: “These Phase 3 results reinforce the potential of zasocitinib as a meaningful oral treatment option for people living with moderate-to-severe plaque psoriasis. We are encouraged by the high levels of skin clearance observed in this study and remain committed to advancing innovative therapies that may help address unmet needs for patients in Canada.”
Next Steps
The LATITUDE Atlas study is part of a broader development program for zasocitinib in psoriasis. Takeda plans to continue analyzing the data and pursue regulatory submissions.
